Atlas Trials

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Clinical trial NCT02934464 · UNKNOWN

Trial details

NCT number
NCT02934464
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Stomach Neoplasms
Start date
2016-12-01
Primary completion
2021-12-01
Enrollment
280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.